James Samuel Shannon, Director at Xilio Therapeutics, Inc. (XLO), bought 5,000 shares at $8.79 ($44K) on 2026-03-26, disclosed to the SEC on 2026-03-30.
Open-market purchase of $44k XLO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| HZNP | SELL | 2019-09-13 | $661K | — | Filing → |